Previous Close | 43.96 |
Open | 39.85 |
Bid | 43.00 |
Ask | 47.10 |
Strike | 165.00 |
Expire Date | 2025-01-17 |
Day's Range | 39.60 - 43.96 |
Contract Range | N/A |
Volume | |
Open Interest | 1 |
Krystal Biotech (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Krystal Biotech (KRYS) soars 36.5% on strong uptake of its newly approved drug Vyjuvek and encouraging pipeline progress.
Amidst a robust week for U.S. stocks, fueled by significant advancements in AI and cloud computing from major technology firms, the market landscape appears increasingly conducive to exploring growth opportunities. In this context, companies with high insider ownership can be particularly compelling, as they often signal strong confidence from those who know the business best.